Andrew Scott walks a group of engaged stakeholders through Global Liver Institute’s reasoning about developing the plan in the first place, the Plan’s four key platforms and some early progress with legislation and developing local leaders. The other Surfers ask questions and then begin to share their own perspectives, with Louise Campbell reiterating the vital importance educating families and Stephen Harrison identifying a set of physician targets for NASH education.
This conversation is sponsored by a grant from Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is leading the field of NASH therapeutic development with resmetirom, a thyroid receptor beta agonist with potential to address both the liver pathophysiology and fibrosis caused by NASH.
TOPICS: AASLD, cirrhosis, Diabetes, Diagnostic Tests, DrugTrial, education, Fatty Liver, FDA, Global Liver Institute, Madrigal, NAFLD, NASH, non-invasive liver testing, Obesity, Patient Advocacy, PNAFLD, social policy,
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast
